Excaliard Pharmaceuticals focused on the development of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. Its lead compound, EXC 001, was an antisense oligonucleotide drug targeting expression of CTGF that is activated during skin scarring following the wound healing process.  RiverVest was a founder of Excaliard.

Acquired by Pfizer in December 2011.